Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials

Código QR

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials

David Wirta1, Amanda M VanDenburgh2, Emily Weng3, Scott M Whitcup4, Sef Kurstjens5, Frederick C Beddingfield III4,61Private Practice, Newport Beach, CA, USA; 2Clinical Development, 3Biostatistics, 4Research and Development, 5Global Drug Development, Allergan, Inc, Irvine, CA, USA; 6Department of Med...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wirta D, VanDenburgh A, Weng E, Whitcup S, Kurstjens S, Beddingfield F 3rd
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/426dcbdab9104b9089a9f1ff9b7ba3f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee A, et al.
Publicado: (2013)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Abayomi B Ogundele, et al.
Publicado: (2010)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura T, et al.
Publicado: (2012)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin J-E, et al.
Publicado: (2011)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2014)

An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
por: Borchert M, et al.
Publicado: (2016)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Moataz E Gheith, et al.
Publicado: (2008)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Abayomi B Ogundele, et al.
Publicado: (2010)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf S, et al.
Publicado: (2016)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study
por: Deshpande SS, et al.
Publicado: (2017)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee D, et al.
Publicado: (2017)

Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
por: Wirta DL, et al.
Publicado: (2021)

Si0.97Ge0.03 microelectronic thermoelectric generators with high power and voltage densities
por: Ruchika Dhawan, et al.
Publicado: (2020)

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
por: Hassan Sajjad Rathore, et al.
Publicado: (2021)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen J, et al.
Publicado: (2017)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
por: Shen J, et al.
Publicado: (2018)

Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
por: Martin P, et al.
Publicado: (2020)

Bimatoprost in the treatment of eyelash hypotrichosis
por: Simon K Law
Publicado: (2010)

Improved electrochemical properties of LiNi0.91Co0.06Mn0.03O2 cathode material via Li-reactive coating with metal phosphates
por: Kyoungmin Min, et al.
Publicado: (2017)

Generation of heterozygous (MRli003-A-1) and homozygous (MRli003-A-2) MYH10 knockout human iPSC lines
por: Fangfang Zhang, et al.
Publicado: (2021)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell JH, et al.
Publicado: (2014)

Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre
por: Gupta S, et al.
Publicado: (2021)

Effect Of Intracameral Phenylephrine And Ketorolac 1.0%/0.3% On Intraoperative Pain And Opioid Use During Cataract Surgery
por: Donnenfeld ED, et al.
Publicado: (2019)

Periorbital muscle atrophy associated with topical bimatoprost therapy
por: Wang PX, et al.
Publicado: (2014)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
por: Scott D Smid
Publicado: (2009)

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies
por: Haghniaz R, et al.
Publicado: (2016)

Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
por: Higashiyama T, et al.
Publicado: (2018)

Ophthalmic epidemiology
Publicado: (1994)

Ophthalmic genetics
Publicado: (1994)

Ophthalmic research
Publicado: (1970)

RPM 03 de Febrero 1998
por: Banco Central de Chile
Publicado: (2020)

Temperature-dependent and time-dependent effects of hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3: in vitro studies
por: Haghniaz R, et al.
Publicado: (2015)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
por: Malhotra R, et al.
Publicado: (2012)

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
por: Bruce I Gaynes, et al.
Publicado: (2008)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
por: Inoue K, et al.
Publicado: (2012)